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Abstract 
Introduction 
The main purpose of this study was to determine if jaw tracking or non-jaw tracking is the 
superior technique for patients with multiple brain metastasis that are treated with Volumetric 
Modulated Radiation Therapy (VMAT) Stereotactic Radiosurgery (SRS). Doses to the organs at 
risk (OAR) and the target volumes were analyzed using the dose volume histogram (DVH) and 
dose statistics for each plan. The goal of this study included analyzing the dosimetric effect on 
the organs at risk and the normal tissue when using jaw tracking versus non jaw tracking. The 
pros and cons for each technique were identified as well as which situations were most positively 
or negatively affected using each technique. 
Methods 
Two different techniques of VMAT SRS treatment were compared for 10 Radiation Therapy 
patients with multiple metastatic brain lesions treated within a single isocenter. Treatment plans 
of patients who have been previously treated with VMAT SRS were retrospectively studied.  The 
initial jaw tracking plan for each patient was edited to remove the jaw tracking component while 
keeping all other parameters the same. The non-jaw tracking plan was created by taking the 
maximum field size from the jaw tracking plan and locking it in as the new field size. The new 
plan was then optimized with the same objectives to obtain a comparable non-jaw tracking plan. 
Results 
Based on the DVH and dose statistics it was determined that the only statistically significant 
difference between the jaw tracking and non-jaw tracking methods was for the maximum dose to 
the optic chiasm, which had decreased maximum doses for 9 out of 10 patients when using the 
jaw tracking plan. The structures that benefited from the jaw tracking technique had the most 
impact in the low dose regions, mainly in the volumes receiving 2- 6 Gray (V2-V6). Jaw tracking 
also decreased the global maximum dose in 9 out of 10 patients by 0.4%- 2.5%.  
Conclusion 
Similar target coverage can be obtained with both jaw tracking and non- jaw tracking plans. The 
benefit comes from the jaw tracking plan having the ability to close the jaws continuously to 
match the shape of the multi- leaf collimator (MLC) as it rotates around the patient. There was 
some benefit in dose reduction to OARs with jaw tracking over non jaw tracking, but with SRS 
the smaller tumor volumes in addition to the distance to OARs caused this study to not provide 
statistically significant results. The OARs saw the most sparing in the low dose region in the 
normal tissue further from the target volumes. The jaw tracking technique would likely produce 
more significant results with larger target volumes that are closer to or even abutting the OARs.  
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Introduction 
Brain Metastasis (BM) is a condition that affects approximately 200,000 people each year 
in the United States, affecting men and women equally.1,2 Brain metastasis occurs when cancer 
cells from a primary tumor site spread to the brain.3 The cancers that spread to the brain most 
frequently are lung, which accounts for up to 20% of BM, breast, melanoma, renal, and 
colorectal.2,4 The incidence of BM is 10 times more common than primary brain tumors; one in 
every three adults with cancer will be affected with BM at some point. 1 Cancer patients are 
living longer due to advances in detection and treatment, so the frequency of BM is on the rise.2 
Advances in systemic therapy have played a large role in the length of survival, but due to the 
nature of the blood brain barrier those agents are unable to reach the brain to protect it against 
disease.1  
In the past, the presence of BM was considered a poor prognostic indicator, and it was  
viewed as the end stage of cancer with only 1 month of life expectancy with no treatment at all. 
Then, the addition of steroids extended life expectancy to 2 months, and in the 1980s the addition 
of whole brain radiotherapy (WBRT) with steroids further increased survival to 4–6 months.2,5 
More recently, Yamamoto et al determined that the extent of a patient’s systemic disease and 
how well it responds to systemic treatment are more likely to affect survival rates than the 
presence of BM.1 In 2012, a new prognostic index was developed for BM that is unique to the 
type of primary cancer. The Disease Specific- Graded Prognostic Assessment (DS-GPA) now 
takes more components into account such as extracranial disease status, patient age, amount of 
brain metastases, functional status, and for breast cancer, the molecular subtype.1 Due to the 
increase in life expectancy in patients with BM there is an increasing need to spare the organs at 
risk (OAR) to lower their risk of developing secondary neoplasm or late side effects such as 
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myelitis and cataracts. 6,7 Over the years several radiation therapy techniques have been used for 
the treatment of BM, each one aiming to decrease dose to the OAR more than the last. 
 The original standard of treatment for brain metastases was WBRT alone since WBRT 
could be started quickly, was convenient, and could treat both detectable and undetectable BM. 
1,5 The standard dose-fractionation scheme for WBRT is treatment to a total of 3000 centi-gray 
(cGy) over the course of 10-12 days.1  The main objectives of treatment included alleviation of 
neurologic symptoms, increasing local control, increasing life expectancy and increasing the 
quality of life. 2,5 Although WBRT had many benefits it was also known to cause increased 
fatigue and decreased neurocognitive function. 1,2 In the 1990s multiple clinical trials agreed that 
upfront resection of symptomatic solitary brain metastasis in addition to WBRT resulted in a 
longer progression-free survival and increased local control compared to using WBRT alone. 
Other advantages included the ability to obtain a histological diagnosis when necessary, and 
avoid the long-term use of steroids which can cause side effects such as myopathy, 
immunosuppression, osteoporosis, and gastrointestinal complications.1,2,8 The use of surgical 
resection for brain metastasis has made many advances over the past two decades and remains an 
important regimen for the treatment of solitary metastatic brain lesions larger than 3 cm that 
cause neurologic deficits.1,2 Although surgery has proved to be beneficial in the treatment of 
solitary metastatic brain lesions, there is inadequate sound documentation assessing the role of 
surgery for multiple metastatic brain lesions.2  
In the 1980s a less-invasive approach, stereotactic radiosurgery (SRS), was implemented 
clinically. 1 SRS is defined by the American Association of Neurological Surgeons (AANS) and 
the American Society for Therapeutic Radiology and Oncology (ASTRO) as “a distinct 
neurosurgical discipline that utilizes externally generated ionizing radiation to inactivate or 
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eradicate defined targets in the head or spine without need to make an incision.”2   Credited to 
the neurosurgery field, SRS was probably the single most important development for the 
treatment of BM.5 Since the implementation of SRS there have been great advances in imaging, 
radiation treatment planning, and radiation treatment machines which have led to SRS evolving 
into one of the most predominant neurosurgical treatment methods for multiple brain 
conditions.2,5 In the early stages SRS was used to treat single BM lesions in a single fraction, but 
more recently, due to the above mentioned advances, the cutoff for number of lesions treated 
simultaneously is becoming less crucial.1 The implementation of SRS now allows for precise 
planning and conformal treatment of the BM without having to treat the whole brain.5  There are 
many advantages of using SRS including shorter treatment duration, high likelihood of treated-
lesion control, minimal delay in resuming systemic therapy, less cognitive function loss, and 
minimal adverse effects to normal tissue when following standard dose/volume 
recommendations.1,5 In the instance of recurrence, SRS for salvage purposes is another 
advantage for patients previously treated with SRS and/or WBRT.5  
Hypofractionated SRS has been increasingly utilized to help spare normal tissues when 
treating bulky, unresectable lesions and lesions located near radiosensitive structures. Hypo 
fractionated SRS is also called hypo fractionated stereotactic radiotherapy (SRT), and it allows 
the treatment duration to be spread out over 3-5 treatments on consecutive days, or every other 
day. One of the reasons for spreading the treatment over more days allows the normal tissues a 
chance to recover in order to reduce toxicity. The SRT regimens that are most commonly used 
are 25 Gray (Gy) in 5 fractions, and 21 Gy in 3 fractions, although the optimal dose/fractionation 
scheme for SRT is undefined.1  
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There was once a treatment scheme that included WBRT in addition to SRS. 1 SRS can 
increase the local control rate, but with the addition of WBRT the local control rate could 
increase even more, although toxicity from WBRT was still a concern.1,2 In 2006-2011, three 
studies tested whether WBRT could be eliminated from patients receiving SRS. The results of 
these trials proved the addition of WBRT for up to 4 BM decreased local recurrence and 
provided prophylaxis against distant recurrence while SRS alone resulted in an increase of 
distant recurrence. Although there was an increase of distant brain metastases in patients treated 
with SRS alone, 25% of patients with upfront WBRT also developed new distant BM following 
WBRT. It was determined that withholding WBRT lowered the risk of cognitive impairment and 
did not affect survival. In response to this new information, ASTRO issued a recommendation in 
2014 discouraging the addition of WBRT to SRS for patients with limited BM.1  
In addition to the evolution of BM treatment techniques, the treatment machines 
themselves have evolved. Within the head of a modern-day linear accelerator (linac) is a set of 
jaws which provide secondary collimation of the treatment field size, and under the jaws is a 
tertiary collimation called the multileaf collimator (MLC). 7 Depending on the linac model, the 
MLCs are made of up to 120- 160 individual leaves that can move during treatment to 
continuously shape the field to the size of the tumor. 
 MLCs are essential for modern external beam radiation therapy.7 For the treatment of 
WBRT, 3D conformal technique is used in which the MLC leaves for the treatment fields are 
fixed in a position that correspond to the projection of the target volume from the beams eye 
view. Fixed MLC leaves were the standard until the development of Intensity Modulated 
Radiation Therapy (IMRT). IMRT allows for modulation of dose across each of multiple 
treatment fields by using dynamic MLCs. With sliding window IMRT, the MLCs move 
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continuously during the treatment of each field and then the gantry of the linac is moved 
manually to the next treatment position. The introduction of Volumetric- Modulated Arc 
Therapy (VMAT) in 2008 enhanced this technology by adding the ability for the modulation of 
dose rate and MLC position as the gantry simultaneously rotates around the patient. 9  
Prior to recent advances in SRS, each BM was given its own isocenter. For patients with 
multiple BM this could result in very long treatment times, up to several hours in some cases. 
More recently VMAT has allowed for the treatment of multiple BM within a single isocenter, 
which can drastically decrease the treatment time to a few minutes without sacrificing accuracy.1 
This is a huge advancement for the comfort of the patient alone. The goal of radiation therapy is 
to deliver maximum dose to a tumor while minimizing doses to normal structures. The 
implementation of VMAT for SRS has proven to be exceptional in achieving this goal while 
improving SRS outcomes.9,10 Although advanced, VMAT still delivers a low nominal dose due 
to the interleaf leakage of the MLCs.10 The solution to this problem is Jaw Tracking.  
Jaw tracking is a technique that was developed by Varian for the True Beam linear 
accelerator; it was implemented starting in the Eclipse V.10.0 treatment planning software 
(TPS).10,11 Jaw tracking adds the ability of the main collimator jaws to continually adjust and 
track the shape of the MLCs during treatment, minimizing the radiation leakage through the 
MLC leaves. 7,10,11 This allows for increased shielding of the normal tissues around the 
tumor.10,11 Since jaw tracking plans have been shown to better spare the OAR, the probability of 
developing a secondary neoplasm or late side effects may decrease.6,7 Jaw tracking has also 
proven to be advantageous for treatment of patients who have local recurrence or a second 
primary malignant neoplasm in or beside a previously treated area.6 
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 The significance of jaw tracking is all about minimizing unnecessary interleaf leakage.  
Cadman et al., found that the transmission through the MLC and jaws combined is less than 
0.1% of the original intensity.12 Losasso et al., found that MLC transmission increases with an 
increase in jaw field size and beam energy.13 For various jaw sizes the transmitted dose rate 
when shielded by MLCs alone could be 0.90%- 4.40% for 6MV and 1.14-7.00% for 18MV, 
higher than that shielded by jaws or both MLC and jaws.7 The Eclipse TPS has a dose 
calculation algorithm that takes the collimator scatter during jaw movement into account.10  
Many studies have shown the potential of jaw tracking in reducing radiation doses to 
normal organs by using different radiation delivery techniques.10 Yao et al., compared the 
dosimetric differences between jaw tracking and no jaw tracking in 16 static IMRT plans. This 
study included 8 plans with large tumor volumes that were compared with 8 plans with small 
tumor volumes. This study concluded that jaw tracking can reduce the dose to OAR, and the 
plans with large tumor volumes showed more significant results than the plans with small tumor 
volumes.11  Feng et al., compared dynamic IMRT versus static jaw IMRT on 28 different plans 
with various tumor locations. This study showed that the jaw tracking plans resulted in lower 
mean doses in the whole body as well as in the low dose regions such as the V5,V10, V20, V30, 
and V40.6 
In addition to IMRT, the effects of jaw tracking in VMAT plans have also been explored. 
Thongsawad et al., compared the effects of jaw tracking versus non-jaw tracking in prostate, 
lung, and nasopharynx VMAT plans. With jaw tracking, it was observed that there was a 
decrease in the low dose regions of V5 and V10 for the OAR, and an overall decrease in mean 
dose to the lung. For integral dose there was a significant decrease in almost all of the treatment 
plans by using jaw tracking, and a large reduction was seen in the V5.10 Wu et al., compared 
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identical VMAT plans with and without jaw tracking while keeping all other plan details 
constant. Jaw tracking resulted in decreased doses to both the tumor volume and OAR without 
sacrificing the delivery efficiency of the VMAT plans.7 
Most publications discussed the dose changes in several kinds of tumors, but very few 
studied the impact of tumor sizes. Schmidhalter et al., indicated that integral-dose reduction was 
dependent on the tumor size; for example, a large size difference between anterior and lateral 
views in a head and neck tumor can create larger range of jaw movement.14  In multiple lesion 
VMAT SRS, the tumor volumes will likely be small, but considering there can be multiple 
targets treated by one isocenter, the maximum jaw width at different angles is likely to produce 
significant results when using jaw tracking versus non jaw tracking.  
The main purpose of this study was to determine the potential advantages of using jaw 
tracking with VMAT SRS for the treatment of multiple metastatic brain lesion within a single 
isocenter. The goals of this study include analyzing the dosimetric effects on the organs at risk 
and the normal tissue, change in MU, and difference in max field width when using jaw tracking 
versus non jaw tracking.  
Null hypothesis (Ho): In VMAT SRS for patients with multiple brain metastases jaw 
tracking will not show a lowered dose to organs at risk and normal tissue compared to using non 
jaw tracking. 
Alternative hypothesis (Ha): In VMAT SRS for patients with multiple brain metastases 
jaw tracking will show a lowered dose to organs at risk and normal tissue compared to using non 
jaw tracking. 
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Methods and Materials 
Patient Selection 
 This is a retrospective study that includes 10 male and female patients who were previously 
treated at a Southeast hospital for multiple lesion brain metastases using the VMAT SRS technique 
with jaw tracking. A list was obtained from the billing department that outlined patients who had 
been previously charged for an SRS treatment. From the list, patients were selected for the study 
if they met a certain criterion. They were all treated previously using the VMAT SRS technique 
with jaw tracking, had multiple metastatic brain lesions treated in one isocenter, had the same 
critical structures delineated by the same dosimetrist, and had the same prescription which utilized 
the 10MV FFF beam on the Varian True Beam linear accelerator. A new plan was created based 
off the previous plan to do a comparison. There was no harm to the patient because the new plan 
was only created for the purpose of data collection, and it was not meant to be implemented 
clinically. 
IRB 
 Prior to seeking the approval from the Institutional Review Board (IRB), the required CITI 
program courses were completed through Grand Valley State University. The research proposal 
was presented to the hospital IRB board. Details about the study were presented along with the 
plan for handling Protected Health Information (PHI). The hospital approved this study under the 
exempt status. In order to comply with the Health Insurance Portability and Accountability Act of 
1996 (HIPPA), the hospital implemented a “Data Management Procedure” for all research 
investigators to follow. This agreement involved guidelines for safely acquiring and storing PHI. 
To safely store patient data, the hospital created a confidential folder on the network that could 
only be accessed by the research investigators. After obtaining IRB approval from the hospital, the 
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IRB board at Grand Valley State University also approved this study as exempt. During the study, 
all patient data was stored in the confidential network folder with patient identifiers removed
 Each patient was simulated in a GE LightSpeed RT Wide Bore 16 Slice CT simulator. A 
QFix Portrait Intracranial Head & Neck Device was indexed on the CT Simulator table with a 
CIVCO lockbar. The patients laid in the supine position with their head rested on a customized 
QFix cushion which was supported underneath by a clear headrest. A 3.2mm QFix Assure Open 
View U-frame aquaplast mask was custom made for each patient, and then it was immobilized to 
the treatment table. All patients kept their arms by their side and were given a knee cushion for 
support. After the fabrication of all devices, each patient was scanned with 1.25 mm slice thickness 
in the head-first supine (HFS) position. Prior to releasing the patient, the Radiation Oncologist 
verified the set-up and reviewed the CT Simulation scan. 
Planning 
 Post simulation, Eclipse treatment planning System (TPS) version 15 was utilized for the 
reconstruction and planning of each patient. To maintain consistency, all plans that were chosen 
for this study were created and contoured by the same Dosimetrist, and planned on the same 
LINAC, the Varian True Beam. All prior imaging studies were fused, and all critical structures 
were delineated by the Dosimetrist prior to the Radiation Oncologist setting an isocenter and 
contouring the Gross Tumor Volumes (GTV). After the GTVs were delineated, the Dosimetrist 
followed the same planning technique for each patient. First, the GTVs were all combined to create 
a “Total GTV” structure that would be used for planning purposes only. From the GTV there were 
three rings added, an inner control, middle control, and outer control as seen in Figure 1 in the 
appendix. Starting at the edge of the GTV, a 5mm inner control ring was created. From the outer 
edge of the inner control ring, a 5 mm margin was added to create the middle control ring. Then, 
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the outer control ring was created by adding a 5mm ring starting at the outer edge of the middle 
control ring. 
  After all planning structures were completed, 10 MV Flattening Filter Free (FFF) SRS 
Rapid Arc fields were added to each plan and MLCs were fit to the “GTV Total” planning 
volume to optimize the collimator jaws. Each field was visualized in the beams eye view (BEV) 
window and the parameters, including the collimator, were set with the goal of minimizing the 
maximum field size and minimizing island blocking. Each patient in this study was prescribed a 
hypofractionated regimen of 3000 cGy over the course of 5 fractions. The plans were optimized 
as shown in Table 1, then calculated using the Anisotropic Analytical Algorithm (AAA) and a 
dose grid size of 0.15 cm. After calculation, all plans were normalized at 100% to the lesion with 
the least coverage. When evaluating each plan, special attention was placed on producing a plan 
with a conformality index less than 1.5, gradient between 3-5, and dose bridging the 50% isodose 
line between lesions was avoided if possible. The International Commission on Radiation Units 
and Measurements (ICRU) 62 calculates the conformality index as the ratio of the volume 
enclosed by the prescription isodose surface (VRx) to the volume of the PTV (VPTV). The 
conformality index defines how well the tumor volume is being covered by the treatment.  
Gradient index (GI) is a tool to evaluate intermediate dose fall off, is the ratio of the volume 
enclosed by half of the prescription isodose and the prescription isodose volume. 15  
For the evaluation of both plans, an SRS protocol from the University of Alabama at 
Birmingham (UAB) was followed in which constraints were defined for organs at risk. The 
constraints that were followed were for hypofractionated SRS treatment when treating 4-6 Gy per 
fraction in 5 fractions. Dose constraints are as follows: brain minus PTV- maximum dose < 20 Gy, 
mean dose < 6 Gy, brainstem- maximum dose < 31 Gy, V26 Gy < 1cc, chiasm and optic nerve- 
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maximum dose < 25 Gy, V20 Gy < 0.2cc, cochlea- max dose < 27.5 Gy, lens- max dose < 3-7 Gy, 
and spinal cord- max dose < 30 Gy, V22.5 < 0.25cc (Table 2). 
For this study, each plan was copied into a new course labeled “Research”. The previously 
treated plan was labeled as “Jaw Tracking” (JT) and it was duplicated to create a non-jaw tracking 
(NJT) plan. For the NJT plan the MLCs were deleted and re-created by using the maximum field 
size from the JT plan. This is the only change that was made prior to optimization. Once in the 
optimization window, the jaw tracking feature was turned off and each plan was re-run starting in 
level 1. To have consistency between the two plans, the optimization objectives were left the same. 
The plans were calculated once again using the AAA and a dose grid size of 0.15 cm. After 
calculation, each plan was once again normalized at 100% to the lesion with the least coverage. 
In the Eclipse treatment planning software, a plan comparison was created for each patient. 
The DVH and dose statistics provided in this plan comparison were analyzed for 10 different 
critical structures. The maximum dose and mean dose for brain-PTV, brainstem, spinal cord, left 
cochlea, right cochlea, left lens, right lens, left optic nerve, right optic nerve, and optic chiasm 
were all evaluated. Due to variations in size and number of tumors in each patient the brain was 
not evaluated. Instead brain-PTV was created by combining the planning target volumes (PTV) of 
each patient to create a total PTV structure. This total PTV structure was then subtracted from the 
brain volume which resulted in the brain- PTV structure that was evaluated.  
Statistical analysis was performed in consultation with Grand Valley State University’s 
Statistics Center using IBM SAS version 9.4 software. Due to the small sample size, nonparametric 
tests were used to see if the median dose for each critical structure differed when using the jaw 
tracking technique and the non-jaw tracking technique. Nonparametric tests are used on data that 
is either counted or ranked, and they are based on fewer assumptions. A nonparametric test can be 
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used if there is a deviation from normal distribution, a difference in the number of subjects in each 
group, and a small sample size.16 Boxplots and histograms were created to analyze symmetry and 
detect outliers. Outliers were observed and symmetry could not be assumed so the sign test was 
performed for the comparison of variables. For this study, the median of each data set was used to 
measure central tendency. The sign test is used to compare differences between two sets of data 
for each patient. When it is not possible to acquire quantitative measures, but rank measures are 
able to be obtained between members of a pair, the sign test is a great tool to use. 16 
Results 
The main purpose of this study was to determine if there were any advantages of using 
jaw tracking with VMAT SRS for the treatment of multiple metastatic brain lesion within a 
single isocenter. The main goal of this study is to obtain a better understanding of the dose 
effects on normal tissues when utilizing the jaw tracking technique as opposed to not using jaw 
tracking, and to determine if there is a significant impact when using one technique over the 
other. The 10 previously treated male and female patients were selected for this study with 
varying amounts of brain metastases ranging from 3- 14 lesions within a single isocenter.  
Brain- GTV 
 The mean doses and max point doses for brain - GTV were evaluated for both plans as 
seen in Table 3 and Table 4. For the jaw tracking plan the mean doses across all 10 subjects 
ranged from 198 cGy- 652 cGy with a median of 479.4 cGy as seen in. For the non- jaw tracking 
plan the mean dose across all subjects ranged from 221.8- 711.8 cGy with a median of 492.2 
cGy.  The median brain – GTV mean dose was higher in the non- jaw tracking plan than the jaw 
tracking plan. A sign test was performed and did not indicate a statistical difference between the 
median jaw tracking and non- jaw tracking mean dose for brain - GTV, p= 0.3438. For the jaw 
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tracking plan the maximum point doses for the brain – GTV across all 10 subjects ranged 
between 3040.8- 3695.4 cGy with a median dose of 3442 cGy. For the non- jaw tracking plan the 
maximum doses across all 10 subjects ranged from 3070.8- 3720.8 cGy with a median dose of 
3470.9 cGy. The median brain – GTV maximum dose was higher in the non- jaw tracking plan 
than the jaw tracking plan. A sign test was performed and did not indicate a statistical difference 
between the median jaw tracking and non- jaw tracking maximum dose for brain - GTV, 
 p= 0.2891.  
Brainstem 
The mean doses and max point doses for the brainstem were evaluated for both plans. For 
the jaw tracking plan the mean brainstem doses across all 10 subjects ranged from 79.9- 1118.1 
cGy with a median dose of 391.3 cGy. For the non- jaw tracking plan the mean brainstem dose 
across all subjects ranged from 94.2-1145.9 cGy with a median of 398 cGy.  The median 
brainstem mean dose was higher in the non- jaw tracking plan than the jaw tracking plan. A sign 
test was performed did not indicate a statistical difference between the median jaw tracking and 
non- jaw tracking mean dose for the brainstem, p= 0.3438. For the jaw tracking plan the 
maximum point doses for the brainstem across all 10 subjects ranged between 217.2-2974.2 cGy 
with a median of 826.4 cGy. For the non- jaw tracking plan the maximum brainstem doses across 
all 10 subjects ranged from 231.4- 2953.3 cGy with a median dose of 1009 cGy. The median 
brainstem max point dose was higher in the non- jaw tracking plan than the jaw tracking plan. A 
sign test was performed and did not indicate a statistical difference between the median jaw 
tracking and non- jaw tracking maximum point dose for the brainstem, p= 0.3438. 
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Spinal Cord 
The mean doses and max point doses for the spinal cord were evaluated for both plans. 
For the jaw tracking plan the mean spinal cord doses across all 10 subjects ranged from 10- 
388.3 cGy with a median dose of 128.7 cGy. For the non- jaw tracking plan the mean spinal cord 
dose across all subjects ranged from 13- 442.4 cGy with a median dose of 117.3 cGy.  The 
median spinal cord mean dose was lower in the non- jaw tracking plan than the jaw tracking 
plan. A sign test was performed and did not indicate a statistical difference between the median 
jaw tracking and non- jaw tracking mean dose for the spinal cord, p= 0.3438. For the jaw 
tracking plan the maximum point doses for the spinal cord across all 10 subjects ranged between 
24.7- 1552.2 cGy with a median dose of 363.7 cGy. For the non- jaw tracking plan the maximum 
spinal cord doses across all 10 subjects ranged from 36- 1713.2 cGy with a median dose of 329.5 
cGy. The median spinal cord max point dose was lower in the non- jaw tracking plan than the 
jaw tracking plan. A sign test was performed and did not indicate a statistical difference between 
the median jaw tracking and non- jaw tracking maximum point dose for the spinal cord,            
p= 0.3438. 
Optic Chiasm 
The mean doses and max point doses for the optic chiasm were evaluated for both plans. 
For the jaw tracking plan the mean optic chiasm doses across all 10 subjects ranged from 158.6-
525.1 cGy with a median dose of 251.3 cGy. For the non- jaw tracking plan the mean optic 
chiasm dose across all subjects ranged from 214.3-521.5 cGy with a median of 262.7 cGy.  The 
median optic chiasm mean dose was higher in the non- jaw tracking plan than the jaw tracking 
plan. A sign test was performed and did not indicate a statistical difference between the median 
jaw tracking and non- jaw tracking mean dose for the optic chiasm, p= 0.7539. For the jaw 
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tracking plan the maximum point doses for the optic chiasm across all 10 subjects ranged 
between 283.5-647.4 cGy with a median dose of 402.7 cGy. For the non- jaw tracking plan the 
maximum optic chiasm doses across all 10 subjects ranged from 340.4- 757.4 cGy with a median 
of 464.8 cGy. The median optic chiasm max point dose was higher the non- jaw tracking plan 
than the jaw tracking plan. A sign test was performed and did indicate a statistical difference 
between the median jaw tracking and non- jaw tracking maximum point dose for the optic 
chiasm, p= 0.0215. 
Left Optic Nerve 
The mean doses and max point doses for the L optic nerve were evaluated for both plans. 
For the jaw tracking plan the mean L optic nerve doses across all 10 subjects ranged from 58.3-
357 cGy with a median of 193.1 cGy. For the non- jaw tracking plan the mean L optic nerve 
dose across all subjects ranged from 50.6-362.7 cGy with a median dose of 199.6 cGy.  The 
median L optic nerve mean dose was higher the non- jaw tracking plan than the jaw tracking 
plan. A sign test was performed and did not indicate a statistical difference between the median 
jaw tracking and non- jaw tracking mean dose for the L optic nerve, p= 1.0. For the jaw tracking 
plan the maximum point doses for the L optic nerve across all 10 subjects ranged between 78.8-
534.1 cGy with a median dose of 298.4 cGy. For the non- jaw tracking plan the maximum L 
optic nerve doses across all 10 subjects ranged from 72.8-540.2 cGy with a median of 304.8 cGy. 
The median L optic nerve point dose was higher in the non- jaw tracking plan than the jaw 
tracking plan. A sign test was performed and did not indicate a statistical difference between the 
median jaw tracking and non- jaw tracking maximum point dose for the left optic nerve,  
p=0 .7539.  
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Right Optic Nerve 
The mean doses and max point doses for the R optic nerve were evaluated for both plans. 
For the jaw tracking plan the mean R optic nerve doses across all 10 subjects ranged from 42.2-
292.2 cGy with a median of 181.9 cGy. For the non- jaw tracking plan the mean R optic nerve 
dose across all subjects ranged from 42.7-292.8 cGy with a median of 209 cGy.  The median R 
optic nerve mean dose was higher in the non- jaw tracking plan than the jaw tracking plan. A 
sign test was performed and did not indicate a statistical difference between the median jaw 
tracking and non- jaw tracking mean dose for the R optic nerve, p= 0.1094. For the jaw tracking 
plan the maximum point doses for the R optic nerve across all 10 subjects ranged between 146.9-
529.9 cGy with a median of 391.5 cGy. For the non- jaw tracking plan the maximum R optic 
nerve doses across all 10 subjects ranged from 75.9-513.9 cGy with a median of 372.4 cGy. The 
median R optic nerve point dose was lower in the non- jaw tracking plan than the jaw tracking 
plan. A sign test was performed and did not indicate a statistical difference between the median 
jaw tracking and non- jaw tracking maximum point dose for the R optic nerve, p= 0.3438.  
Right Lens 
The mean doses and max point doses for the R lens were evaluated for both plans. For the 
jaw tracking plan the mean R lens doses across all 10 subjects ranged from 16-150.8 cGy with a 
median of 67.6 cGy. For the non- jaw tracking plan the mean R lens dose across all subjects 
ranged from 23-142.2 cGy with a median of 82.2 cGy.  The median R lens mean dose was higher 
in the non- jaw tracking plan than the jaw tracking plan. A sign test was performed and did not 
indicate a statistical difference between the median jaw tracking and non- jaw tracking mean 
dose for the R lens, p= 0.3438. For the jaw tracking plan the maximum point doses for the R lens 
across all 10 subjects ranged between 18.6-183.2 cGy with a median of 105.3 cGy. For the non- 
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jaw tracking plan the maximum R lens doses across all 10 subjects ranged from 28.6-174.2 cGy 
with a median of 115.6 cGy. The median R lens max point dose was higher in the non- jaw 
tracking plan than the jaw tracking plan. A sign test was performed and did not indicate a 
statistical difference between the median jaw tracking and non- jaw tracking maximum point 
dose for the R lens, p= 0.7539.  
Left Lens 
The mean doses and max point doses for the L lens were evaluated for both plans. For the 
jaw tracking plan the mean L lens doses across all 10 subjects ranged from 55.7-129.2 cGy with 
a median of 85.9 cGy. For the non- jaw tracking plan the mean L lens dose across all subjects 
ranged from 47.2-142 cGy with a median of 82.1 cGy.  The median L lens mean dose was lower 
in the non- jaw tracking plan than the jaw tracking plan. A sign test was performed and did not 
indicate a statistical difference between the median jaw tracking and non- jaw tracking mean 
dose for the L lens, p= 0.3438. For the jaw tracking plan the maximum point doses for the L lens 
across all 10 subjects ranged between 87.9-161.3 cGy with a median of 118.7 cGy. For the non- 
jaw tracking plan the maximum L lens doses across all 10 subjects ranged from 72.9-208.2 cGy 
with a median of 97.9 cGy. The median L lens max point dose was lower in the non- jaw 
tracking plan than the jaw tracking plan. A sign test was performed and did not indicate a 
statistical difference between the median jaw tracking and non- jaw tracking maximum point 
dose for the L lens, p= 0.3438.  
Right Cochlea 
The mean doses and max point doses for the R cochlea were evaluated for both plans. For 
the jaw tracking plan the mean R cochlea doses across all 10 subjects ranged from 59.1-618.5 
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cGy with a median of 259 cGy. For the non- jaw tracking plan the mean R cochlea dose across 
all subjects ranged from 63.7-723.9 cGy with a median of 562.4 cGy.  The median R cochlea 
mean dose was higher in the non- jaw tracking plan than the jaw tracking plan. A sign test was 
performed and did not indicate a statistical difference between the median jaw tracking and non- 
jaw tracking mean dose for the R cochlea, p= 0.3438. For the jaw tracking plan the maximum 
point doses for the R cochlea across all 10 subjects ranged between 80.3-1073.5 cGy with a 
median of 326.2 cGy. For the non- jaw tracking plan the maximum R cochlea doses across all 10 
subjects ranged from 106.4-1191.9 cGy with a median of 338.1 cGy. The median R cochlea max 
point dose was higher in the non- jaw tracking plan than the jaw tracking plan. A sign test was 
performed and did/ did not indicate a statistical difference between the median jaw tracking and 
non- jaw tracking maximum point dose for the R cochlea p= 0.1094.  
Left Cochlea 
The mean doses and max point doses for the L cochlea were evaluated for both plans. For 
the jaw tracking plan the mean L cochlea doses across all 10 subjects ranged from 105.2- 675.7 
cGy with a median of 258.8 cGy. For the non- jaw tracking plan the mean L cochlea dose across 
all subjects ranged from 143.1-549.2 cGy with a median of 249 cGy.  The median L cochlea 
mean dose was lower in the non- jaw tracking plan than the jaw tracking plan. A sign test was 
performed and did not indicate a statistical difference between the median jaw tracking and non- 
jaw tracking mean dose for the L cochlea, p= 1.0. For the jaw tracking plan the maximum point 
doses for the L cochlea across all 10 subjects ranged between 113.5-882.4 cGy with a median of 
318 cGy. For the non- jaw tracking plan the maximum L Cochlea doses across all 10 subjects 
ranged from 167.6-827.9 cGy with a median of 320.1 cGy. The median L cochlea max point 
dose was higher in the non- jaw tracking plan than the jaw tracking plan. A sign test was 
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performed and did not indicate a statistical difference between the median jaw tracking and non- 
jaw tracking maximum point dose for the L cochlea p= 0.7539. 
This study demonstrates that the median values of the mean doses to brain-GTV, 
brainstem, optic chiasm, optic nerves, lenses, cochlea, and spinal cord are not significantly 
different in the two plans (all p values > 0.05) as shown in Table 3. Jaw tracking resulted in a 
1.7% - 54% decrease in the median value of the mean doses to OARs in 7 out of 10 patients. 
With the jaw tracking plan, the right cochlea had the largest decrease in mean dose at 54%.  
Also shown in this study is that the median values of the maximum doses to brain-GTV, 
brainstem, optic nerves, lenses, cochlea, and spinal cord are not significantly different in the two 
plans (all p values > 0.05), as shown in Table 4. Jaw tracking resulted in a 0.7% to 18.1% 
decrease in the median maximum dose to OARs in 7 out of 10 patients. The only OAR which 
showed a statistically significant difference between the two plans was the maximum dose to the 
optic chiasm (p value = 0.0215). In addition to OAR comparisons, the global maximum dose to 
the whole body was evaluated for all plans. The data in Table 5 shows that the jaw tracking plan 
decreased the global maximum dose by 0.4%- 2.5% in 9 out of 10 plans. In the other plan the 
global maximum doses were the same. 
Discussion 
 The purpose of this study was to analyze two different treatment planning techniques 
when treating multiple metastatic brain lesions in one isocenter with VMAT SRS. The two 
techniques, jaw tracking and non- jaw tracking were created and the dosimetric effects to organs 
at risk and normal tissues were evaluated. For this study, the mean and maximum doses to the 
OARs, global maximum dose, and DVH were evaluated. 
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OAR Maximum and Mean Dose 
Out of the maximum doses, using the jaw tracking technique resulted in lower median 
values for brain- GTV, optic chiasm, left optic nerve, right lens, right cochlea, and left cochlea.  
Using the non-jaw tracking technique resulted in lower median values for the brainstem, right 
optic nerve, left lens, and spinal cord. Out of the mean doses, using the jaw tracking technique 
resulted in lower median values for brain- GTV, brainstem, optic chiasm, left optic nerve, right 
optic nerve, right lens, and right cochlea. Using the non- jaw tracking technique resulted in lower 
median values for the left lens, left cochlea, and cord. The optic chiasm was the only structure to 
have a lower maximum dose in all 10 jaw tracking plans which resulted in it being the only 
structure with a statistically significant decrease.  
Global Maximum Dose 
Global maximum dose was also evaluated for both techniques. Out of the 10 patients, 9 
saw a 0.4%- 3.1% reduction in the global maximum dose when using the jaw tracking technique. 
The remaining patient had no change in global maximum dose when going from one plan to the 
other. The reduction in global maximum dose when using the jaw tracking technique is possibly 
due to the jaws closing down to block any unnecessary radiation from reaching the patient 
caused by inter- and intra- leaf leakage as the MLCs continuously reposition to align with the 
targets. Figure 2 illustrates the MLC and jaw configuration for the same lesions at the same 
gantry angle for both jaw tracking and non-jaw tracking techniques. This shows the jaws 
remaining in the fixed position for the maximum field size needed for the non- jaw tracking plan 
compared to how much it can be closed when using jaw- tracking. 
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DVH Analysis 
DVH analysis for each patient showed the biggest difference in dose between jaw 
tracking and non- jaw tracking occurs in the V2- V5 region as shown in Figure 3. This means the 
low doses further from the target volume can be better spared by jaw tracking. In this study the 
patients had small, spherical lesions which created small openings in the MLCs. This study 
showed there was not a significant difference when using jaw tracking versus non- jaw tracking 
in VMAT SRS for multiple brain lesions. This study did show that the same findings, although 
small, can be applied to other situations and likely show a more significant response. 
Thongsawad et al. indicated that a reduction in integral dose is dependent on the tumor shape; for 
example a large size difference between the anterior and lateral views in a large, irregular shaped 
lung tumor could create a bigger difference in jaw positions. 10 With irregular shaped tumors the 
jaw tracking would be able to close the jaws simultaneously with the MLCs as the gantry rotates 
around the patient. With large, irregular shaped volumes, the beam’s eye view (BEV) of the 
target volume can be smaller at some gantry angles and larger as it rotates around. Jaw tracking 
allows the jaws to close when the gantry reaches the smaller BEV of the volume, and in a chest 
patient the difference between these two treatment techniques should be more pronounced. 
Another instance that jaw tracking would be beneficial is in the treatment of young patients, or 
patients who are treated for something curative such as lymphoma. Because jaw tracking has 
shown to benefit the low dose regions, this could help prevent secondary malignancies such as 
breast cancer, lung cancer, soft tissue sarcomas, thyroid cancer, and cardiovascular diseases from 
forming due to radiation treatment. 17 
The main differences in the two techniques were likely due to the MLC leakage created 
in the periphery through the beam shaping process. The jaw tracking plan is able to continuously 
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adjust the jaws to the edge of the MLCs whereas the jaws in the non- jaw tracking plan stay fixed 
at the maximum field size needed to cover the widest point in the target. Yao et al. concluded 
there was a correlation between field size and dose reduction to OARs when using jaw tracking 
versus non- jaw tracking. “With small lesions, the field size is small, so the leakage to the OARs 
is also small. The impact of jaw tracking is more obvious in large tumors because the jaw 
tracking technique can block more MLC transmission in large field sizes and reduce the dose to 
out-of-field OARs.” 11 These results agree with the findings of this study. 
Limitations and future research 
 Limitations of this study include having a small sample size as well as it being conducted 
retrospectively. Due to the small sample size of 10 patients, non-parametric measures had to be 
utilized for analysis. Another limitation is the volume of the lesions being small and spherical. 
Due to the small, spherical volumes there were times when certain MLC leaves did not have to 
move or modulate as much as they did when larger lesions were involved. Also, most OARs 
were far enough away from the GTV that they did not seem to be affected as much as they would 
if they had been in closer proximity. 
 Further research could include analysis of tumor volumes in the treatment of multiple 
metastatic lesions when treated with VMAT SRS. These volumes could be compared using jaw 
tracking versus non- jaw tracking to determine if dose to OARs were significantly different 
between the two techniques when volume is considered.  Output for these plans could also be 
compared to see if they correlate with the findings from the dose statistics and DVH. Further 
research could compare jaw tracking versus non- jaw tracking when using VMAT to treat other 
areas in the body which could contain larger, irregular shaped fields that are in closer proximity 
to OARs. 
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Conclusion 
Similar target coverage, conformality, and gradient can be obtained with both jaw 
tracking and non- jaw tracking plans. The benefit comes from the jaw tracking plan having the 
ability to close the jaws continuously to match the shape of the multi- leaf collimator (MLC) as it 
rotates around the patient. There was some benefit in dose reduction to OARs with jaw tracking 
over non jaw tracking, but with SRS the smaller tumor volumes in addition to the distance to 
OARs caused this study to not provide statistically significant results. The OARs saw the most 
sparing in the low dose region between V2- V5 in the normal tissues further from the target 
volumes. This could be beneficial in preventing secondary cancers when treating young or 
curative patients. The jaw tracking technique would likely produce more significant results with 
larger target volumes that are closer to or even abutting the OARs.  
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Appendix 
Figure 1. Dose control rings used in optimization 
 
 
 
Table 1. Dose Objectives 
Structure Objective Type Percent of Prescription Priority 
Target lower objective 102% of Rx 100% 
Inner Control upper objective 98% of Rx 150% 
Middle Control upper objective 50% of Rx 100% 
Outer Control upper objective 40% of Rx 100% 
Brain-GtV * include in cost function 
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Table 2. CNS Normal Tissue Constraints 
Hypofractionation (4.0- 6.0 Gy per fraction) 
    
Organ  Constraint 
Brain  5 fractions: Max dose 20 Gy 
         Mean dose 6 Gy1 
Brainstem  3 fractions: Max dose 23 Gy, V18 Gy < 1cc 
    5 fractions: Max dose 31 Gy, V26 Gy < 1cc 
Chiasm/ Optic Nerve  3 fractions: Max dose 19.5 Gy, V15 Gy < 0.2 cc 
    5 fractions: Max dose 25 Gy, V20 Gy < 0.2 cc 
Cochlea  3 fractions: Max dose 20 Gy 
    5 fractions: Max dose 27.5 Gy 
Lens      Max dose 3-7 Gy 
Retina      Max dose 5-15 Gy 
Spinal Cord  3 fractions: Max dose 18-20 Gy 
  4 fractions: Max dose 26 Gy, V20.8 < 0.35cc 
    5 fractions: Max dose 30 Gy, V22.5 < 0.25cc 
1As more lesions are added this may be hard to achieve. 
 
 
Table 3. Mean Dose to Organs at Risk  
 
Jaw Tracking 
 
Non- Jaw Tracking 
 
Sign Test 
  Min Max Median   Min Max Median 
 
p Value 
Brain-GTV 198 cGy 652 cGy 479.4 cGy 
 
221.8 cGy 711.8 cGy 492.2 cGy 
 
1 
Brainstem 79.9 cGy 1118.1 cGy 391.3 cGy 
 
94.2 cGy 1145.9 cGy 398 cGy 
 
0.3438 
Optic Chiasm 158.6 cGy 525.1 cGy 251.3 cGy 
 
214.3 cGy 521.5 cGy 262.7 cGy 
 
0.7539 
L. Optic Nerve 58.3 cGy 357 cGy 193.1 cGy 
 
50.6 cGy 362.7 cGy 199.6 cGy 
 
1 
R. Optic Nerve 42.2 cGy 292.2 cGy 181.9 cGy 
 
42.7 cGy 292.8 cGy 209 cGy 
 
0.1094 
R. Lens 16 cGy 150.8 cGy 67.6 cGy 
 
23 cGy 142.2 cGy 82.2 cGy 
 
0.3438 
L. Lens 55.7 cGy 129.2 cGy 85.9 cGy 
 
47.2 cGy 142 cGy 82.1 cGy 
 
0.3438 
R. Cochlea 59.1 cGy 618.5 cGy 259 cGy 
 
63.7 cGy 723.9 cGy 562.4 cGy 
 
0.3438 
L. Cochlea 105.2 cGy 675.7 cGy 258.8 cGy 
 
143.1 cGy 549.2 cGy 249 cGy 
 
1 
Spinal Cord 10 cGy 388.3 cGy 128.7 cGy 
 
13 cGy 442.4 cGy 117.3 cGy   0.3438 
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Table 4. Maximum Dose to Organs at Risk  
 
Jaw Tracking 
 
Non- Jaw Tracking 
 
Sign Test 
  Min Max Median   Min Max Median   p Value 
Brain-GTV 3040.8 cGy 3695.4 cGy 3442 cGy 
 
3070.8 cGy 3720.8 cGy 3470.9 cGy 
 
0.2891 
Brainstem 217.2 cGy 2974.2 cGy 826.4cGy 
 
231.4 cGy 2953.3 cGy 1009 cGy 
 
0.3438 
Optic Chiasm 283.5 cGy 647.4 cGy 402.7 cGy 
 
340.4 cGy 757.4 cGy 464.8 cGy 
 
0.0215 
L. Optic Nerve 78.8 cGy 534.1 cGy 298.4 cGy 
 
72.8 cGy 540.2 cGy 304.8 cGy 
 
0.7539 
R. Optic Nerve 146.9 cGy 529.9 cGy 391.5 cGy 
 
75.9 cGy 513.9 cGy 372.4 cGy 
 
0.3438 
R. Lens 18.6 cGy 183.2 cGy 105.3 cGy 
 
28.6 cGy 174.2 cGy 115.6 cGy 
 
0.7539 
L. Lens 87.9 cGy 161.3 cGy 118.7 cGy 
 
72.9 cGy 208.2 cGy 97.9 cGy 
 
0.3438 
R. Cochlea 80.3 cGy 1073.5 cGy 326.2 cGy 
 
106.4 cGy 1191.9 cGy 338.1 cGy 
 
0.1094 
L. Cochlea 113.5 cGy 882.4 cGy 318 cGy 
 
167.6 cGy 827.9 cGy 320.1 cGy 
 
0.7539 
Spinal Cord 24.7 cGy 1552.2 cGy 363.7 cGy   36 cGy 1713.2 cGy 329.5 cGy   0.3438 
 
 
Table 5. Global Body Maximum Dose in cGy 
 
JT Max Dose 
 
NJT Max Dose 
 
Percent (%) Change 
Patient 1 3837 cGy 
 
3837 cGy 
 
No change 
Patient 2 3583 cGy 
 
3644 cGy 
 
1.7% reduction with JT 
Patient 3 3696 cGy 
 
3798 cGy 
 
1.1% reduction with JT 
Patient 4 3727 cGy 
 
3807 cGy 
 
2.2% reduction with JT 
Patient 5 3523 cGy 
 
3600 cGy 
 
2.2% reduction with JT 
Patient 6 3568 cGy 
 
3661 cGy 
 
2.5% reduction with JT 
Patient 7 3606 cGy 
 
3721 cGy 
 
3.1% reduction with JT 
Patient 8 3693 cGy 
 
3707 cGy 
 
0.4% reduction with JT 
Patient 9 3616 cGy 
 
3642 cGy 
 
0.8% reduction with JT 
Patient 10 3645 cGy   3680 cGy   1.0% reduction with JT 
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Figure 2. Same patient with identical treatment parameters- Jaw Tracking vs. Non- Jaw Tracking 
 
 
 
Figure 3. DVH showing the low dose region of the OARs for jaw tracking and non-jaw tracking 
 
 
 
